Abstract Details

Title APOmorphine infusion and aMYLoid deposition in Parkinson’s disease (APOMYL): preliminary clinical and amyloid imaging data

Topic Movement Disorders

Presentation(s) P3 - Poster Session 3 (5:30 PM-6:30 PM)

Poster/Presentation
Number 10-032

Objective to explore the potential effects of chronic Apomorphine infusion treatment on reducing brain Amyloid-β (Aβ) deposition in Parkinson’s disease (PD).

Background a majority of PD patients will develop functionally significant cognitive decline and Aβ plaque deposits have been implicated as a major contributor. Transgenic Alzheimer disease mice treated with Apomorphine show a decrease of intraneuronal Aβ and an improvement of memory function. In cognitively normal PD patients, a neuropathological study has shown that ante-mortem Apomorphine exposure significantly reduces Aβ deposition in the brain.

Design/Methods

preliminary descriptive cross-sectional open label analysis of seven PD patients on chronic continuous Apomorphine infusion treatment who underwent [¹⁸F] florbetaben PET/CT scan, as surrogate marker for brain amyloid deposition, as part of the APOMYL study at King’s College Hospital (London UK). Amyloid was scored as present or absent. Clinical data was collected from medical records and Non-motor Longitudinal International Study (NILS; UKCRN No: 10084). Data is presented as mean (range).

Results seven PD patients (mean age 70.6 (55.6-80.6) years, disease duration 14.1 (5-23) years, median Hoehn-and-Yahr stage 4 (2-5) had undergone amyloid PET/CT scans. The patients were on continuous Apomorphine infusion (daily dose 61.9 (45-96) mg) for 51.1 (10-180) months. Mean Mini Mental State Examination score was 27.2 (24-29), Non-motor symptom (NMS) questionnaire score 11.9 (6-15), NMS scale total score 65.0 (50-88) and SCOPA scores 20 (14-28) for part A, 14 (6-18) for part B, and 5 (1-6) for part C. None of the patients showed abnormal Ab accumulation on PET/CT.

Conclusions

Although open label, this study provides the world-first real-life evidence that Apomorphine infusion may be protective against cerebral Aβ accumulation in PD. Control data is required to confirm this finding and studies are in progress.

Authors/Disclosures
Daniel van Wamelen PRESENTER	No disclosure on file
Marios Politis, MD (Neurodegeneration Imaging Group)	No disclosure on file
Dag Aarsland, MD (King's College London)	Dr. Aarsland has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche Diagnostics.
Per Odin	Per Odin has received personal compensation in the range of $500-$4,999 for serving as a Consultant for AbbVie. Per Odin has received personal compensation in the range of $0-$499 for serving as a Consultant for Britannia. Per Odin has received personal compensation in the range of $0-$499 for serving as a Consultant for Convatec. Per Odin has received personal compensation in the range of $0-$499 for serving as a Consultant for UCB.
Teus Van Laar, MD, PhD	No disclosure on file
Tove Henriksen, MD (Bispebjerg Hospital)	Dr. Henriksen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for AbbVie. Dr. Henriksen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Nordic infucare. Dr. Henriksen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Britannia. Dr. Henriksen has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lundbeck . Dr. Henriksen has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for convatec. Dr. Henriksen has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for AbbVie. Dr. Henriksen has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Nordic Infucare. Dr. Henriksen has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Britannia.
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file

��ɫ��

��ɫ��